Skip to main content
OpenTrials
Completed

NCT Number: NCT04477668

Helmet Non-Invasive Ventilation for COVID-19 Patients

Study hypothesis: Non-invasive positive pressure ventilation delivered by helmet will reduce 28-day all-cause mortality in patients with suspected or confirmed severe COVID-19 pneumonia and acute hypoxemic respiratory failure

Completed

Looking for future studies?

Notify Me

Key information

Age range

14 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Intensive Care Department, King Abdulaziz Medical City, National Guard Health Affairs

Riyadh, 11426, Saudi Arabia

About this study

This will be a pragmatic parallel randomized control trial that will compare helmet nonivasive ventilation with standard of care to standard of care alone in 1:1 ratio. The trial will be implemented in multiple centers.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Suspected or confirmed COVID-19
  • Aged ≥14 years old at the participating ICU. ICUs that use other age cut-off for adult patients will adhere to their local standard (16 or 18 years)
  • Acute hypoxemic respiratory failure based on PaO2/FiO2 ratio <200 despite supplemental oxygen with a partial or non-rebreathing mask at a flow rate >10 L/min or above
  • Intact airway protective gag reflex
  • Able to follow instructions (e.g. squeeze hand on command, eye contact with care provider, stick out tongue on command, etc.)

Exclusion criteria

  • Prior intubation during this hospital admission
  • Cardiopulmonary arrest
  • Glasgow coma scale <12
  • Tracheostomy
  • Upper airway obstruction
  • Active epistaxis
  • Requirement for more than one vasopressor to maintain mean arterial pressure > 65 mm Hg
  • Pregnancy
  • Imminent intubation
  • Patients with do not intubate orders or equivalent
  • Enrolled in another trial for which co-enrolment is not approved including trials on mechanical ventilation
  • Patients already treated with helmet
  • Patients with chronic carbon dioxide retention (PaCO2 >45)
  • Previous enrolment in this trial
  • The primary cause of respiratory failure is not heart failure as judged by the treating team

Treatment and study plan

Helmet non-invasive ventilation

Device

Patients will be allocated to helmet non-invasive ventilation

Primary outcomes

  1. 28-day all-cause mortality

    Time frame: 28 days from randomization

    all cause mortality

Secondary outcomes

  1. Intubation rate within 28 days

    Time frame: 28 days from randomization

    endotracheal intubation

  2. ICU mortality

    Time frame: 180 days from randomization

    ICU death

  3. Hospital mortality (censored at day 180)

    Time frame: 180 days from randomization

    hospital death

  4. Hospital length of stay

    Time frame: 180 days from randomization

    length of stay in the hospital

  5. ICU free days at day 28

    Time frame: 28 days from randomization

    days not in ICU

  6. Invasive ventilation-free days at day 28

    Time frame: 28 days from randomization

    days without ventilator support

  7. Renal replacement therapy-free days at day 28

    Time frame: 28 days from randomization

    days without renal replacement therapy received

  8. Vasopressor-free days at day 28

    Time frame: 28 days from randomization

    days without vasopressor support

  9. Safety outcome: skin pressure ulcers

    Time frame: 28 days from randomization

    presence of pressure ulcers

  10. Safety outcome: barotrauma

    Time frame: 28 days from randomization

    incidence of barotrauma

  11. Serious adverse events (including cardiovascular events and device complications)

    Time frame: 28 days from randomization

    reporting of abovementioned adverse events

  12. 180-day all-cause mortality

    Time frame: 180 days from randomization

    all cause mortality

  13. Follow-up study: 180-day 5-level EQ-5D version

    Time frame: 180 days from randomization

    The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems.

Sponsors and collaborators

Lead sponsor

King Abdullah International Medical Research Center

Other

Collaborators

  • Al Amiri Hospital, Kuwait
  • Aseer Central Hospital, Abha, Saudi Arabia
  • King Abdulaziz Medical City, Riyadh, Saudi Arabia
  • King Abdulaziz University
  • King Fahad Hospital, Madinah, Saudi Arabia
  • King Fahd Hospital of the University, Al Khobar, Saudi Arabia
  • King Faisal Specialist Hospital & Research Center
  • King Saud Medical City

Registry information

Acronym: Helmet-COVID

Important dates

Study start
2021
Primary completion
2021
Study completion
2022
First posted
Jul 20, 2020
Registry last updated
Sep 9, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.